You are not logged in. | Log in
In Progress
Clinical

Mid-gestational gene expression profile in placenta and link to pregnancy complications - GSE37901

Purpose

Data on the temporal dynamics of human placental gene expression is scarce. We have completed the first whole-genome profiling of human placental gene expression dynamics (GeneChips, Affymetrix®) from early to mid- gestation (10 samples; gestational weeks 5 to 18) and report 154 genes with considerable change in transcript levels (FDR P<0.1). Functional enrichment analysis revealed >200 GO categories that are statistically over-represented among 105 genes with dynamically increasing transcript levels. Analysis in an extended sample (n=43; gestational weeks 5 to 41) conformed a highly significant (FDR P<0.05) expressional peak in mid-gestation placenta for ten genes: BMP5, CCNG2, CDH11, FST, GATM, GPR183, ITGBL1, PLAGL1, SLC16A10, STC1. A central hypothesis of our study states that the aberrant expression of genes characteristic to mid-gestation placenta may contribute to affected fetal growth, maternal preeclampsia (PE) or gestational diabetes (GD). The gene STC1 coding for Stanniocalcin 1 (STC1) was identified with a sharp placental expressional peak in mid-gestation, increased mRNA levels at term and significantly elevated STC1 protein levels in post-partum maternal plasma in all pregnancy complications. The highest STC1 levels were identified in women, who developed simultaneously PE and delivered an SGA baby (median 731 vs 418 pg/ml in controls; P=0.001). CCNG2 and LYPD6 exhibited significantly increased placental mRNA expression and enhanced intensity of immunohistochemistry staining in placental sections all studied in GD and PE cases. Aberrant expression of mid-gestation specific genes in pregnancy complications at term indicates the importance of the fine-scale tuning of the temporal dynamics of transcription regulation in placenta. Observed significantly elevated plasma STC1 in complicated pregnancies warrants further investigations of its potential as a biomarker. Interestingly, a majority of genes with high expression in mid-gestation placenta have also been implicated in adult complex disease. This observation promotes a recently opened discussion on the role of placenta in developmental programming.

Hypothesis

--

Experimental Design

4 samples; this submission is extension of our earlier study (accession GSE22490).

Experimental Variables

--

Controls

--

Methods

--

Additional Information

--

Microarray
Affymetrix HG-U133_Plus_2
4 Samples Loaded: 4
Human (Homo sapiens)
placenta
Sample Set Spreadsheet
Please log in in order to upload files.
Samples Preview
Sample ID !Sample_title tissue gestational age
GSM929667 13_4_MPG_18 placenta 18
GSM929668 14_5_MPG_17.1 placenta 17.1
GSM929669 15_6_MPG_17.3 placenta 17.3
GSM929670 16_8_MPG_18.8 placenta 18.8
Please log in in order to upload files.
File
Log2 Transformed
  •   |  View in GXB »
Clinical Datasource
Links

Samples Viewer / Editor

All fields are editable except the "Sample ID" column. To edit a cell, click within the cell. To edit a "date" cell, click on the calendar icon. To cancel an edit, press the ESC key.

Sample ID !Sample Title Tissue Gestational age
GSM929667
13_4_MPG_18
placenta
18
GSM929668
14_5_MPG_17.1
placenta
17.1
GSM929669
15_6_MPG_17.3
placenta
17.3
GSM929670
16_8_MPG_18.8
placenta
18.8

Group Sets View in Gene Expression Browser

Name  
All Samples Default  View
In order to make new Group Sets or change settings, please log in.

Module Analysis

Group Set  
All Samples
Your bug report has been sent!